A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Non-Small-Cell Lung Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 212 (final count)
- Started
- Sep 14, 2021
- Main results expected
- Aug 28, 2026
- Fully finished
- Jun 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters
Measured over: Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig
Rate of rilvegostomig discontinuation due to toxicity
Measured over: Part A, B, C, D and E: From first dose to the last dose of rilvegostomig (an average of 6 months)
Objective Response Rate (ORR)
Measured over: Part B, C, D and E: From first dose of rilvegostomig to progressive disease (PD) or death in the absence of disease progression (approximately 2 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04995523 · record last updated 2026-07-14 · checked 2026-11-09 15:47 UTC